Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

Related Parents

Related Issuers

PX TALK: Genmab $2.5bn 2-part, $1.5bn 7NC3 sr sec 6.375%A; $1bn 8NC3 sr unsec 7.375%A, pxg today

HYC European Market: Deal Flow - GeneralHYC US Market: Deal Flow - General

Genmab A/S / Genmab Finance LLC (GENMAB) $2.5bn 144A/Reg S notes 2-part. No reg rights.

    - $1.5bn sr sec notes due 2032 (7y). NC3 (MWC T+50bp). Equity claw: 3y 40%. Special call: 10% per year the first 3 years at 103. Ba2/BB+BB+ (stable/stable/stable). Via MS/BofA/GS/Danske/DNBC/Nordea/PNC/TSI jt books. SMR at 100 if the acquisition has not closed by 10/05/26. CoC at 101. Denoms: 200kx1k. IPT: mid 6s. Price talk: 6.375% area.

    - $1bn sr unsec notes due 2033 (8y). NC3 (MWC T+50bp). Equity claw: 3y 40%.  B1/BB-/BB (stable/stable/stable). Via MS sole. SMR at 100 if the acquisition has not closed by 10/05/26. CoC at 101. Denoms: 200kx1k. IPT: mid 7s. Price talk: 7.375% area.

Roadshow 11/12-14 (investor call 11am 11/12)  (TLB lender call 11/10, loan commitments due 11/18 (moved up from 11/19). Books close at 12pm 11/18. Pricing 11/18 afternoon. UOP: along with $2.9bn cash on hand, $1bn sr sec term loan A, $2bn sr sec term loan B, and $500m revolver (undrawn) and cash on hand, to fund the acquisition of Merus NV (MRUS) for $97 per share or approximately $8bn total transaction value, including debt. Closing expected early Q1 2026. Biz: biotechnology company that specializes in the creation and development of differentiated antibody therapeutics to fight against cancer and other serious diseases. HQ: Valby, Denmark. (Announced 09/29/2025). 


We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.